CSPC Pharmaceutical Group Limited (HK:1093)
:1093
Want to see HK:1093 full AI Analyst Report?
1093 Stock Chart & Stats
HK$8.96
HK$0.04(0.91%)
At close: 4:00 PM EST
HK$8.96
HK$0.04(0.91%)
Day’s Range― - ―
52-Week RangeHK$5.34 - HK$11.63
Previous CloseN/A
Volume61.16M
Average Volume (3M)135.86M
Market Cap
HK$96.17B
Enterprise ValueHK$89.42B
Total Cash (Recent Filing)HK$10.63B
Total Debt (Recent Filing)HK$495.00M
Price to Earnings (P/E)22.9
Beta0.74
Next Earnings
Jun 03, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend Yield2.7%
Share Statistics
EPS (TTM)0.04
Shares Outstanding11,522,452,000
10 Day Avg. Volume105,139,995
30 Day Avg. Volume135,859,703
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)1.63
Price to Sales (P/S)1.90
P/FCF Ratio30.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.30Price Target Upside26.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)0.67
Revenue Forecast (FY)HK$31.89B
Bulls Say, Bears Say
Bulls Say
Out-licensing AgreementLandmark out-licensing agreement with a global pharmaceutical partner secures a sizable upfront payment and lets the company lead early clinical development while shifting late-stage commercialization risk.
R&D Strategy And InnovationShift to a global innovation model combined with sustained R&D investment prioritizes differentiated late-stage candidates and supports recurring licensing income.
Sales StabilizationCore finished drug sales are showing sequential growth, indicating stabilization as volume-based procurement headwinds ease and supporting revenue momentum.
Bears Say
Revenue Pressure And Margin RiskRevenue is pressured by volume-based procurement and strict hospital prescription controls, which compress profitability and raise margin risk.
CSPC Pharmaceutical Group News
1093 FAQ
What was CSPC Pharmaceutical Group Limited’s price range in the past 12 months?
CSPC Pharmaceutical Group Limited lowest stock price was HK$5.34 and its highest was HK$11.63 in the past 12 months.
What is CSPC Pharmaceutical Group Limited’s market cap?
CSPC Pharmaceutical Group Limited’s market cap is HK$96.17B.
When is CSPC Pharmaceutical Group Limited’s upcoming earnings report date?
CSPC Pharmaceutical Group Limited’s upcoming earnings report date is Jun 03, 2026 which is in 33 days.
How were CSPC Pharmaceutical Group Limited’s earnings last quarter?
CSPC Pharmaceutical Group Limited released its earnings results on Mar 25, 2026. The company reported HK$0.036 earnings per share for the quarter, missing the consensus estimate of HK$0.157 by -HK$0.121.
Is CSPC Pharmaceutical Group Limited overvalued?
According to Wall Street analysts CSPC Pharmaceutical Group Limited’s price is currently Undervalued.
Does CSPC Pharmaceutical Group Limited pay dividends?
CSPC Pharmaceutical Group Limited pays a Semiannually dividend of HK$0.14 which represents an annual dividend yield of 2.7%. See more information on CSPC Pharmaceutical Group Limited dividends here
What is CSPC Pharmaceutical Group Limited’s EPS estimate?
CSPC Pharmaceutical Group Limited’s EPS estimate is 0.1.
How many shares outstanding does CSPC Pharmaceutical Group Limited have?
CSPC Pharmaceutical Group Limited has 11,522,452,000 shares outstanding.
What happened to CSPC Pharmaceutical Group Limited’s price movement after its last earnings report?
CSPC Pharmaceutical Group Limited reported an EPS of HK$0.036 in its last earnings report, missing expectations of HK$0.157. Following the earnings report the stock price went up 1.921%.
Which hedge fund is a major shareholder of CSPC Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:1093
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSPC Pharmaceutical Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.69%
12-Months-Change
Fundamentals
Return on Equity
11.96%
Trailing 12-Months
Asset Growth
9.88%
Trailing 12-Months
Company Description
CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
1093 Stock 12 Month Forecast
Average Price Target
HK$11.30
▲(26.08% Upside)
Technical Analysis
Sino Biopharmaceutical
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Shanghai Pharmaceuticals Holding Co
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---